CervoMed (NASDAQ:CRVO) Upgraded by Brookline Cap M to Strong-Buy Rating

Brookline Cap M upgraded shares of CervoMed (NASDAQ:CRVO) to a strong-buy rating in a report published on Tuesday,Zacks.com reports. Brookline Cap M also issued estimates for CervoMed’s Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($2.65) EPS.

A number of other analysts have also weighed in on CRVO. Cantor Fitzgerald initiated coverage on shares of CervoMed in a research note on Thursday, December 18th. They set an “overweight” rating on the stock. Zacks Research upgraded shares of CervoMed from a “strong sell” rating to a “hold” rating in a report on Monday, January 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of CervoMed in a research report on Thursday, December 18th. Brookline Capital Acquisition raised shares of CervoMed to a “strong-buy” rating in a research report on Tuesday. Finally, D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of CervoMed in a research note on Tuesday, December 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.17.

CervoMed Price Performance

Shares of NASDAQ CRVO traded up $0.71 during mid-day trading on Tuesday, hitting $5.31. The company had a trading volume of 105,761 shares, compared to its average volume of 81,486. The company has a market capitalization of $49.13 million, a PE ratio of -1.83 and a beta of -0.82. CervoMed has a 1-year low of $1.92 and a 1-year high of $16.94. The business’s 50-day simple moving average is $7.45 and its 200 day simple moving average is $8.16.

CervoMed (NASDAQ:CRVO) last released its earnings results on Friday, November 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). CervoMed had a negative return on equity of 76.78% and a negative net margin of 415.27%.The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $1.43 million. On average, analysts expect that CervoMed will post -1.88 EPS for the current year.

Insider Buying and Selling

In other news, CEO John J. Alam acquired 10,793 shares of the company’s stock in a transaction on Monday, November 17th. The shares were bought at an average price of $8.46 per share, with a total value of $91,308.78. Following the completion of the acquisition, the chief executive officer owned 12,500 shares in the company, valued at $105,750. This trade represents a 632.28% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Matthew Winton bought 3,500 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were purchased at an average price of $8.43 per share, for a total transaction of $29,505.00. Following the transaction, the insider directly owned 13,500 shares of the company’s stock, valued at approximately $113,805. This represents a 35.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 92,000 shares of company stock worth $737,723 in the last ninety days. 35.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CervoMed

Several hedge funds have recently made changes to their positions in the business. Citizens Financial Group Inc. RI increased its position in CervoMed by 23.0% in the 4th quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock valued at $296,000 after acquiring an additional 7,000 shares during the period. Byrne Asset Management LLC purchased a new position in shares of CervoMed in the 4th quarter valued at approximately $116,000. Citadel Advisors LLC purchased a new position in shares of CervoMed in the 3rd quarter valued at approximately $247,000. Two Sigma Investments LP acquired a new position in shares of CervoMed in the third quarter valued at approximately $138,000. Finally, Readystate Asset Management LP purchased a new stake in shares of CervoMed during the third quarter worth approximately $118,000. Institutional investors and hedge funds own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.